In adipocytes, phosphorylation and activation of PDE3B is a key event in the antilipolytic action of insulin. The role of PDE4, another PDE present in adipocytes, is not yet known. In this work we investigate the role of PDE3B and PDE4 in insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis. Inhibition of PDE3 (OPC3911, milrinone) but not PDE4 (RO 20-1724) lowered insulin-induced glucose uptake and lipogenesis, especially in the presence of isoproterenol (a general β-adrenergic agonist), CL316243, a selective β3-adrenergic agonist, and pituitary adenylate cyclase-activating peptide. The inhibitory effect of OPC3911 was associated with reduced translocation of GLUT-4 from the cytosol to the plasma membrane. Both OPC3911 and RO 20-1724 increased protein kinase A (PKA) activity and lipolysis. H89, a PKA inhibitor, did not affect OPC3911-mediated inhibition of insulin-induced glucose uptake and lipogenesis, whereas 8-pCPT-2'-O-Me-cAMP, an Epac agonist which mediates PKA independent cAMP signaling events, mimicked all the effects of OPC3911. Insulin-mediated activation of protein kinase B, a kinase involved in insulininduced glucose uptake, was apparently not altered by OPC3911. In summary, our data suggest that PDE3B, but not PDE4, contributes to the regulation of insulin-induced glucose uptake, GLUT-4 translocation, and lipogenesis presumably by regulation of a cAMP/ Epac signalling mechanisms.
Introduction
Cyclic nucleotide phosphodiesterases (PDEs) 1 are important regulators of signal transduction processes mediated by cAMP and cGMP. Eleven PDE families (PDE1-11) have been identified with regard to their substrate affinities, biochemical and physical properties, mechanisms whereby they are regulated, and different sensitivities to inhibitors [1, 2] . In adipocytes, PDE3B (the PDE3 family consists of two members, PDE3A and PDE3B) plays a key role in the antilipolytic action of insulin [3] . Insulin-induced phosphorylation and activation of PDE3B leads to increased hydrolysis of cAMP, lowering of protein kinase A (PKA) activity and thereby a decrease in PKA-dependent phosphorylation and activation of hormone sensitive lipase and lipolysis [4] .
In adipocytes, modulators of cAMP regulate insulin-induced glucose uptake, a process known to involve translocation of insulin sensitive glucose transporters (GLUT-4) from an intracellular pool to the plasma membrane [5] . However, different effects of these agents have been reported. Thus, cAMP-increasing β-adrenergic agonists have been shown to increase [6, 7] , to have no effect on [8, 9] , or to decrease [10] [11] [12] insulin-induced glucose uptake in adipocytes. Studies using PDE3 inhibitors, OPC3911 and cilostamide, showed impaired, [13, 14] or unaffected [15] insulin-induced glucose uptake in adipocytes. The role of PDE4, which is also expressed in adipocytes, is not known. RO 20-1724, a PDE4 inhibitor, was found to suppress insulin-induced glucose uptake in myocardium [16] , and another PDE4 inhibitor, rolipram, decreased glucose uptake in vivo in brain, heart, and skeletal muscle [17] .
In this study we evaluated the role of PDE3B and PDE4 in insulin-induced glucose uptake, GLUT-4 translocation, and lipogenesis. We found that inhibition of PDE3B, but not PDE4, resulted in lowering of all these insulin-induced processes. Furthermore, overexpression of PDE3B resulted in increased lipogenesis. On the other hand, inhibition of PDE3B and PDE4, respectively, increased PKA activity and lipolysis to similar extent. An Epac agonist was found to mimic, whereas H89, a PKA inhibitor did not interfere with the ability of OPC3911
to inhibit insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis. These results indicate that PDE3B is involved in regulation of insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis, presumably by regulating cAMP/ Epac signalling events.
Materials and methods

Preparation of adipocytes
Adipocytes were isolated from epididymal fat pads of 36-38 day-old male Sprague-Dawley rats (B&K Universal, Stockholm) and prepared as described previously [18, 19] . Lund University Ethic Committee approved the study (permission number: M170-03).
Lipolysis assay
Glycerol release was measured as described previously [22] . Four hundred microliter aliquots of 5% (v/v) adipocytes in KRH were incubated as indicated in "Results" for 30 min at 37 o C with shaking. Reactions were stopped by putting the tubes on ice for 20 min. One milliliter of hydrazine buffer containing 50 mM glycine (pH 9.8), 0.05% hydrazine hydrate, 1 mM MgCl 2, supplemented with 0.75 mg/ml ATP, 0.375 mg/ml nicotinamide adenine dinucleotide, 25 µg/ml glycerol-3-phosphate dehydrogenase, and 0.5 µg/ml glycerokinase was added to 200 µl of collected media. After incubation for 40 min in room temperature, OD 340 was measured and glycerol release was calculated.
Glucose uptake assay
2-deoxy-D-[1-
3 H]-glucose uptake was measured as described [20] . 
Lipogenesis assay
Lipogenesis was measured as previously described [21] . 
Subcellular fractionation of adipocytes
Seven milliliter aliquots of 10% (v/v) adipocytes in KRH were incubated as indicated in "Results" for 10 min at 37 o C. Cells were then homogenized in 3 ml of homogenization buffer (40 mM HEPES, 10 mM NaF, 1 mM dithioerythriol, 1 mM phenylmethylsulphonylfluoride, 0.25 mM sodium orthovanadate, 10 μg/ml antipain, 10 μg/ml leupeptin and 1 μg/ml pepstatin A, pH 7. 
SDS-PAGE and western blot analysis
After protein concentration had been measured (Bradford [23] ), the samples were mixed with 
Adenovirus infection and cell treatment
High titer adenoviral stocks (approximately 10 10 pfu/ml) were used to infect primary rat adipocytes (2-3 ml of 12 % cells) as indicated in the figure legend. Infection was performed for16 hours in DMEM supplemented with 0.5% BSA and 5% FCS at 37°C, 5% CO 2 . Control virus expressing β-galactosidase (AdVβ-gal) and adenoviral vectors were kindly provided by Drs. C.N. Newgard and H. Mulder. Flag-PDE3B-expressing virus (AdFlag-PDE3B) was constructed as previously described [25] .
Determination of PDE3 activity
Primary adipocytes infected for 16 hours with AdV β -gal or AdVPDE3B-Flag were washed in KRH buffer and homogenized (10 strokes at room temperature) in homogenization buffer (50 mM N-tris(hydroxymethyl)-methyl-2-aminoethanesulfonic acid (TES), 40 mM p-nitrophenyl-phosphate, 2 mM EGTA, 1 mM EDTA, 250 mM sucrose, 1 mM dithioerytritol, 0.05 mM vanadate, 10 µg/ml antipain, 10 µg/ml leupeptin, 1 µg/ml pepstatin A, pH 7.4). The cell homogenates were centrifuged at 33000 x g for 45 min at 4°C and the crude membrane fractions were resuspended in homogenization buffer. PDE3 activity was measured as described previously [26] . Assays were performed at 30°C for 15 min. 
Data analysis
Results
PDE3B regulates insulin-induced glucose uptake, GLUT-4 translocation to the plasma membrane and lipogenesis
As shown in We also tested the effects of OPC 3911 and RO 20-1724 on insulin-induced glucose uptake in the presence of pituitary adenylate cyclase-activating peptide (PACAP) and CL316243 (β 3 -adrenergic receptor agonist), which through interaction with G-protein linked receptors increase cAMP and lipolysis [29, 30] . The inhibitory effect of OPC3911 on insulin-induced glucose uptake was potentiated in the presence of both PACAP and CL316243 (data not shown) as was the case for isoproterenol. On the other hand, the inhibitory effect of OPC3911
was not potentiated by adenosine deaminase (ADA) which increases cAMP by degradation of adenosine (leading to removal of adenosine receptor mediated inhibition of adenylate cyclase).
Having shown that OPC3911 is a potent inhibitor of insulin-induced glucose uptake and lipogenesis, we next investigated whether the inhibitory effect was related to changes in GLUT-4 translocation from the cytosol to the plasma membrane. As shown in Fig. 3 , shown [29] . Milrinone, another PDE3 inhibitor, inhibited insulin-induced lipogenesis in the same manner as OPC3911 (data not shown). RO 20-1724 had little or no effect on insulininduced lipogenesis. Lipogenesis was also studied in adipocytes overexpressing PDE3B.
Infection of 3T3-L1 adipocytes with AdVFlag-PDE3B led to a 35-fold overexpression of PDE3B (Fig. 4A, B) , which resulted in almost 4-fold increase in lipogenesis as compared to control cells infected with AdVβ-gal (Fig. 4C) . These findings are in agreement with reduced lipogenesis in adipocytes treated with PDE3 inhibitors.
As shown in (data not shown) and lipogenesis ( Fig. 6) is further supported by the findings that H89, a PKA inhibitor, did not reverse these effects.
Epac is expressed in adipocytes and 8-pCPT-2'-O-Me-cAMP lowers insulin-induced glucose uptake, GLUT-4 translocation to the plasma membrane and lipogenesis
PKA independent cAMP signalling pathways have been described [31, 32] and cAMP has been shown to interact with GTP exchange factors, GEFs or Epacs (Exchange Proteins directly Activated by cAMP). Epac-mediated signaling was recently found to play a role in exocytosis [33] , and in the activation of protein kinase B (PKB) [34] , two events highly relevant for insulin-induced glucose uptake. As shown in Fig. 7 , presenting western blots from total homogenate and subcellular fractions of adipocytes, Epac is expressed in adipocytes. In order to test the possibility that the inhibitory effect of OPC3911 on glucose transport and lipogenesis might be mediated by regulation of a PKA-independent pathway, an
Epac agonist, 8-pCPT-2'-O-Me-cAMP was used. As shown in Fig. 8, 8 -pCPT-2'-O-MecAMP mimicked the ability of OPC3911 to reduce insulin-induced glucose uptake and lipogenesis. We then examined the influence of 8-pCPT-2'-O-Me-cAMP on GLUT-4 translocation and as shown in Fig. 9 , the Epac agonist was able to impair translocation of GLUT-4 from an intracellular pool to the plasma membrane suggesting that the PKAindependent effects of OPC3911 could be mediated via cAMP/ Epac signalling.
Activation of PKB by insulin has been suggested to have an important role in glucose uptake and GLUT4 translocation [35] and Epac has recently been found to be involved in PKB activation [34] . However, as shown in Fig. 10 , insulin-induced phosphorylation of PKB was not reduced in the presence of OPC3911, either without or with isoproterenol. It has also been demonstrated that insulin induces activation of the MAP kinase cascade, as well as cross-talk between β-adrenergic receptors and the MAP kinase in adipocytes [36] . However, addition of PD98059, an inhibitor of MEK (MAP kinase kinase), did not interfere with the ability of OPC3911 to inhibit insulin-induced glucose uptake or lipogenesis (data not shown).
Discussion
In this work we provide evidence that PDE3B, a key enzyme in the antilipolytic action of insulin [3] , is also involved in the regulation of insulin-induced glucose uptake, translocation of GLUT-4 to the plasma membrane and lipogenesis in primary rat adipocytes. Treatment of adipocytes with selective PDE3 inhibitors OPC3911 and milrinone, but not RO 20-1724, a PDE4 inhibitor, resulted in lowering of insulin-induced glucose uptake and lipogenesis. These effects were potentiated by several different agonists known to stimulate receptor-mediated production of cAMP. This is in agreement with a previous study showing that the cAMP analogue, 8-bromo-cAMP, potentiated the ability of OPC3911 to inhibit insulin-induced glucose uptake [13] . On the other hand, ADA which increases cAMP by catalyzing degradation of adenosine [37] and therefore leads to removal of adenosine receptor mediated inhibition of adenylate cyclase, did not potentiate OPC3911 mediated lowering of insulininduced glucose uptake and lipogenesis, suggesting that PDE3B controls specific pools of cAMP. In agreement with some studies [2] , but in contrast to others [38, 39] , we found no inhibition of insulin-induced glucose uptake by the addition of isoproterenol alone. Rather, with regard to insulin-induced lipogenesis, we found a slight potentiation by isoproterenol, in agreement with previous results [29] . Differential effects of various cAMP-modulating agents, and especially the finding that OPC3911 but not RO 20-1724 had effects on insulin- . Most likely PDE3B which is a membrane associated enzyme [3] regulates a cAMP pool different from a pool regulated by PDE4, an enzyme found mainly in the cytosolic fraction of adipocytes [28] . In a number of other cell types [44] [45] [46] and in several PDE3 and PDE4 knock out mice models [47] [48] [49] A correlation between cAMP-mediated inhibition of insulin-induced glucose uptake and inhibition of translocation of GLUT-4 to the plasma membrane has been shown in some studies [8] but not in others [6] . Isoproterenol-induced inhibition of insulin-induced glucose uptake in the presence of ADA was suggested to be caused by trapping of GLUT-4 in occluded vesicles associated with the plasma membrane during exocytosis, rather than by reduction of total plasma membrane GLUT-4 content [6] . Activity of the plasma membrane associated GLUT-4 transporter could explain some of the discrepancy between insulininduced glucose uptake and the amount of GLUT-4 in the plasma membrane. GLUT-4 has been shown to be phosphorylated [7, 50] , and its phosphorylation was associated with the transport activity [7] . Our findings show a clear correlation between total plasma membrane, HDM, and LDM GLUT-4 content and inhibition of insulin-induced glucose uptake caused by OPC3911.
Mechanisms whereby inhibition of PDE3B induces inhibition of insulin-induced GLUT-4 translocation to the plasma membrane and inhibition of insulin-induced glucose uptake are not known. It is possible that PDE3B regulates a cAMP pool activating Epac-induced signalling events. Furthermore, signaling triggered by PDE3B involve targets downstream from PKB or on pathways parallel to the PKB signaling network. It might be possible that a PDE3B-controlled cAMP pool is involved in the regulation of proteins important for the transport or docking/ fusion of GLUT-4 exocytotic vesicles or in the regulation of atypical PKCs, kinases believed to play a role in insulin-induced glucose uptake [51] .
Whether or not the ability of OPC3911 to inhibit insulin-induced lipogenesis can be explained solely by its effects on glucose uptake remains to be established. Most likely, other events downstream of glucose uptake are influenced by PDE3B inhibition since, in the conditions where OPC 3911 did not lower insulin-induced glucose uptake ( Fig. 2A, without ISO) , it significantly lowered insulin-induced lipogenesis (Fig 2B, without ISO ).
In conclusion, PDE3B controls a cAMP pool, which through Epac-mediated signalling events, negatively regulates insulin-induced glucose uptake, GLUT-4 translocation to the plasma membrane, and lipogenesis. Our results suggest that Epacs or signalling components downstream of Epacs are interesting targets for the development of drugs for the treatment of insulin resistance. Bands from 3 experiments were quantified using Fuji LAS 1000 Plus system. Results are expressed as means +/-SEM.
